Biopatch for venous or arterial catheter sites [MIB117]

The technology described in this briefing is Biopatch. It is a hydrophilic foam dressing impregnated with chlorhexidine gluconate (CHG), and is used for covering central venous or arterial catheter sites.

The innovative aspects are that it releases CHG to reduce the risk of catheter-related bloodstream infections (CRBSIs), while the absorbent foam draws discharge away from the catheter site.

The intendedplace in therapy would be as an addition to standard sterile semipermeable transparent dressings to reduce the risk of a CRBSI in people with venous or arterial catheters.

The key points from the evidence summarised in this briefing are from 6 non-UK-based randomised controlled trials in a total of 3,674 adults and children in secondary care settings. Results are mixed with some evidence showing reductions in rates of bacterial colonisation and the number of CRBSIs compared with standard dressings in patients with venous or arterial catheters, and some showing no difference between Biopatch and standard care.

Urethrotech UCD for difficult or failed catheterisation [MIB116]

The technology described in this briefing is the Urethrotech urethral catheterisation device (UCD). It is designed to be used for difficult or failed catheterisations in men.Urethrotech UCD for difficult or failed catheterisation

The innovative aspect is that it is the only currently available system which integrates a guidewire into a standard Foley catheter.

The intended place in therapy would be instead of cystoscopy and supra-pubic catheterisation methods after standard catheterisation has failed, or when it is difficult (such as in men with an enlarged prostate). The device could potentially be used in any healthcare setting by appropriately trained staff.

The main points from the evidence summarised in this briefing are from 2 conference abstracts reporting prospective non-comparative studies including a total of 157 patients in a UK setting. They show that the Urethrotech UCD can be a useful urethral catheterisation method in men, and reported no adverse events.

Biopatch for venous or arterial catheter sites

Medt ech innovation briefing on Biopatch for venous or arterial catheter sites.

The technology described in this briefing is Biopatch. It is a hydrophilic foam dressing impregnated with chlorhexidine gluconate (CHG), and is used for covering central venous or arterial catheter sites.

The innovative aspects are that it releases CHG to reduce the risk of catheter-related bloodstream infections (CRBSIs), while the absorbent foam draws discharge away from the catheter site.

SecurAcath for securing percutaneous catheters

New medical technologies guidance from NICE.on SecurAcath for securing percutaneous catheters

Recommendations:

• The case for adopting SecurAcath for securing peripherally inserted central catheters (PICCs) is supported by the evidence. SecurAcath is easy to insert, well tolerated, associated with a low incidence of catheter-related complications and does not usually need removing while the catheter is in place.
•  SecurAcath should be considered for any PICC with an anticipated medium- to long-term dwell time (15 days or more).
• Cost modelling shows that SecurAcath is cost saving compared with adhesive securement devices if the PICC remains in place for 15 days or longer. Estimated cost savings range from £9 to £95 per patient for dwell times of 25 days and 120 days, respectively. Cost savings result from shorter maintenance times and less need for device replacement with SecurAcath. Annual savings across the NHS in England from using SecurAcath are estimated to be a minimum of £4.2 million.

Catheter-free nephrectomy: A safe change to routine practice

Journal of Clinical Urology.  First Published May 26, 2017 

The aim of this article is to assess any difference in length of stay (LOS), complications and readmission rates between patients who had catheter-free nephrectomy compared to those who had a catheter inserted as routine peri-operatively.

UHCW Research: E. F. Zimmermann.

Reducing Catheter Associated Urinary Tract Infections (CAUTI’s) at a District General Hospital Can change be sustained?

This shared-learning tool describes how Chesterfield Royal Hospital developed an improvement strategy to reduce catheter-associated urinary tract infections after data revealed rates were double the national average.

A clinical audit to assess the compliance of documentation of the urinary catheter care bundle in the inpatient units of Berkshire Healthcare NHS Foundation Trust

From the NICE shared learning database

A clinical audit was undertaken covering the Trust’s inpatient units in order to assess the compliance of staff in the use of documentation for a catheter care bundle for patients with an indwelling catheter in line with the NICE clinical guideline for Healthcare-associated infections: prevention and control in primary and community care (CG139) and the NICE Quality Standard 61 for Infection control and prevention.

Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults

This Cochrane Review informed a practice changing update on Dynamed Plus. It found that antimicrobial coatings that appear to reduce risk of central venous catheter-related bloodstream infection include minocycline-rifampicin, chlorhexidine silver sulfadiazine, silver, and heparin, but antimicrobial coatings do not appear to reduce risk of sepsis or mortality